Switch theme
Sign up to access all valuation multiples
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
2020
100
LTM Revenue $60.7M
LTM EBITDA -$112M
$65.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Invivyd has a last 12-month revenue (LTM) of $60.7M and a last 12-month EBITDA of -$112M.
In the most recent fiscal year, Invivyd achieved revenue of $25.4M and an EBITDA of -$174M.
Invivyd expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Invivyd valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $60.7M | XXX | $25.4M | XXX | XXX | XXX |
| Gross Profit | $56.3M | XXX | $23.8M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | -$112M | XXX | -$174M | XXX | XXX | XXX |
| EBITDA Margin | -184% | XXX | -685% | XXX | XXX | XXX |
| EBIT | -$106M | XXX | -$177M | XXX | XXX | XXX |
| EBIT Margin | -175% | XXX | -697% | XXX | XXX | XXX |
| Net Profit | -$102M | XXX | -$170M | XXX | XXX | XXX |
| Net Margin | -168% | XXX | -669% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Invivyd's stock price is $1.
Invivyd has current market cap of $112M, and EV of $65.0M.
See Invivyd trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65.0M | $112M | XXX | XXX | XXX | XXX | $-0.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Invivyd has market cap of $112M and EV of $65.0M.
Invivyd's trades at 2.6x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Invivyd's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Invivyd has a P/E ratio of -1.1x.
See valuation multiples for Invivyd and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $112M | XXX | $112M | XXX | XXX | XXX |
| EV (current) | $65.0M | XXX | $65.0M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | -0.6x | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInvivyd's last 12 month revenue growth is 204%
Invivyd's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $2.0M for the same period.
Invivyd's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Invivyd's rule of X is 326% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Invivyd and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 204% | XXX | 238% | XXX | XXX | XXX |
| EBITDA Margin | -184% | XXX | -685% | XXX | XXX | XXX |
| EBITDA Growth | -94% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -480% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 326% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 541% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 790% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Invivyd acquired XXX companies to date.
Last acquisition by Invivyd was XXXXXXXX, XXXXX XXXXX XXXXXX . Invivyd acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Invivyd founded? | Invivyd was founded in 2020. |
| Where is Invivyd headquartered? | Invivyd is headquartered in United States of America. |
| How many employees does Invivyd have? | As of today, Invivyd has 100 employees. |
| Who is the CEO of Invivyd? | Invivyd's CEO is Mr. William Duke, M.B.A.. |
| Is Invivyd publicy listed? | Yes, Invivyd is a public company listed on NAS. |
| What is the stock symbol of Invivyd? | Invivyd trades under IVVD ticker. |
| When did Invivyd go public? | Invivyd went public in 2021. |
| Who are competitors of Invivyd? | Similar companies to Invivyd include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Invivyd? | Invivyd's current market cap is $112M |
| What is the current revenue of Invivyd? | Invivyd's last 12 months revenue is $60.7M. |
| What is the current revenue growth of Invivyd? | Invivyd revenue growth (NTM/LTM) is 204%. |
| What is the current EV/Revenue multiple of Invivyd? | Current revenue multiple of Invivyd is 1.1x. |
| Is Invivyd profitable? | Yes, Invivyd is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Invivyd? | Invivyd's last 12 months EBITDA is -$112M. |
| What is Invivyd's EBITDA margin? | Invivyd's last 12 months EBITDA margin is -184%. |
| What is the current EV/EBITDA multiple of Invivyd? | Current EBITDA multiple of Invivyd is -0.6x. |
| What is the current FCF of Invivyd? | Invivyd's last 12 months FCF is -$106M. |
| What is Invivyd's FCF margin? | Invivyd's last 12 months FCF margin is -174%. |
| What is the current EV/FCF multiple of Invivyd? | Current FCF multiple of Invivyd is -0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
